It is well-known that gender differences exist in the onset, progression, and prognosis of cardiovascular diseases (CVDs), [1] and that risk factors such as high blood pressure and lipid profiles vary between men and women. [2] Currently, sex differences are stressed as important variables to take into account when examining the etiology of CVD. Genome-wide association studies of CVD have employed the sex as a covariate in their analytical models, but generally disregarded potential genetic heterogeneity (GHS) attributable to sex. Spurious or biased genetic effects can be produced by ignoring various types of GHS for CVDs (Figure 1) . Only sex-limited CVDs (e.g., gestational hypertension as a female-specific disease) for which genetic factors are analyzed for one sex are free from such biases. The bias might become more serious for the elderly, because genetic effects contribute to more variations in blood pressure and lipid profiles in older people.
[3]  Various sources of information can be utilized with respect to the GHS for CVD. Information on both population risk variants and individual risk values is important to clinical applications regardless of the corresponding reflection of the risk variants on the risk values ( Figure 2 ). The information on the significant variants is often more important for treatment, and the pooled risk assessment is often more important for prevention. It might be essential to provide not only GHS of CVD itself, but also the GHS of its risk factors in understanding the mechanism of GHS ( Figure 2 ). Specific risk factors and standards should be determined for each CVD.
Various analytical methods for explaining GHS were discussed with the corresponding statistical models in a previous study. [4] It was suggested that a sex-influenced disease should be treated as two different diseases (or phenotypes) based on sex in determining genetic factors and in estimating genetic effect size. That is, the genetic analysis should be separately conducted by sex, or a two-disease model could be utilized to treat female data as one disease and male data as another, employing a genetic covariance structure between men and women. Naturally, careful attention should be paid to analysis of the data to avoid confounding genetic effects. When a genetic effect is estimated and/or a genetic association is determined, other genetic factors and environmental factors could be appropriately explained by the analytical model. CVDs are typical complex diseases, inevitably influenced by many genetic factors. Genetic factors can be identified by the Bayesian approach, employing a Markov chain Monte Carlo method to avoid violating transgressive assumptions for genetic analysis of sex-influenced diseases. [4] Risk values can be estimated by the best linear unbiased prediction using genetic covariance among individuals. [5] All of these analyses are based on a mixed model approach that can reflect polygenic effects by examining genetic relationships among individuals. [6] [7] [8] They also control population stratification and thus reduce false positive genetic associations. [9] Although the GHS is reflected in genetic analysis for CVD, a guarded evaluation on the resulting genetic factors is necessary, because they are moving targets produced from a variety of invisible interactions. For example, dimorphic genomic components originated from different structures of the genome (e.g. sex chromosomes) and different pressures of natural selection based on sex (e.g. sexually antagonistic selection) [10] may interact with environmental factors and/or other genetic factors (especially, sex hormone-responsive elements and genes). Thus, it is hard to reflect these hidden conditions in every individual. To reliably estimate the stochastic risk of an individual, a high priority has to be placed on finding a population that shared similar genetic and environmental effects to the individual undergoing examination.
Most genome-wide association studies for CVD have included fixed sex effects as a covariate in analytical models and neglected GHS. These analyses might have failed to identify many sex-specific genetic associations with CVD.
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